Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

Inclusion Criteria: * The patient has histologically proven primary or recurrent squamous cell carcinoma arising in the oropharynx, oral cavity, hypopharynx, larynx, or nasopharynx. * The patient has stage III or IV disease. * Performance status \< 2 (ECOG scale) with a life expectancy of \> 12 months. * Age 19 years and above. * The patient is medically fit to tolerate a course of definitive radiation therapy. * The patient has: 1. adequate hepatic function with bilirubin \< upper limit of normal (ULN) 2. transaminases (SGOT and SGPT) may be up to 2.5 x ULN if alkaline phosphatase is \< ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are \< ULN 3. adequate renal function with serum creatinine \< 1.5 mg/dl (or estimated creatinine clearance of \> 50 mL/min) 4. normal serum calcium 5. adequate hematologic function as: defined by an absolute neutrophil count \> 1500/ml, hemoglobin \> 8.0 g/dl, and platelet count \> 100,000/ml. * The patient may have had a prior malignancy but must be three years from treatment. * A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less then three years will be allowed. * The patient must agree to use effective contraception if procreative potential exists, and continue contraception for at least 6 months following completion of the study. * Patient must sign informed consent. Exclusion Criteria: * The patient has received radiation therapy previously to the head and neck. * The patient has received prior chemotherapy for head and neck cancer. * The patient is pregnant or lactating. * Peripheral neuropathy \> Grade 2. * Serious non-malignant disease (e.g. congestive heart failure, uncontrolled atrial fibrillation, active hepatitis). * Any underlying psychological condition that would prohibit the understanding and rendering of informed consent. * Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 must be excluded.